Servier launches InnoPreP™, Its new preparative chromatography offer under its Contract Development & Manufacturing activity
Paris, France, October 1, 2018 – Servier, an independent international pharmaceutical company, today announced the launch of InnoPreP™ – a new preparative chromatography service offered under its contract development and manufacturing business.
Servier has employed preparative chromatography for over 30 years and its team of experts based in Normandy, France has become a respected leading global authority on this accepted industry standard approach to purification. InnoPreP™ encompasses the capability for either continuous processing using SMB or 6-column batch chromatography at lab to industrial scale, and can reduce time-to-market by as much as three months.
Dr. Gwenaël Servant, Senior Director of Business Development for Servier’s contract development and manufacturing business, said, “We can reduce time to market significantly by getting to the target molecule and into the clinic faster. To be able to do this at industrial volumes is appealing to companies seeking to scale up existing processes or simply move quickly, as it delivers clear financial gains.”
Servier has invested in expansion of its preparative chromatography infrastructure at its fully integrated Bolbec drug substance facility in Normandy, France. A new dedicated 500 m2 space houses continuous processing using simulated moving bed (SMB) technology, which can achieve greater yields from fewer starting materials and is very efficient for racemic separation. There is green technology with Supercritical CO2 and a falling film evaporator recycles up to 90% of solvent.
Lab to industrial scale chromatography is also available using Servier’s batch technology with six-column equipment. The InnoPreP™ area also has high containment to enable handling of highly potent compounds down to OEB 5, serving companies seeking to develop HPAPIs for oncology.
Dr. Christophe Berini, Analytical Innovative Technologies Research Scientist at Servier, said, “The InnoPreP™ approach not only gets our client to their target molecule and into the clinic faster, it also helps to optimize the purity of their APIs and intermediates, and gains them a better understanding of their process, which brings many long-term development benefits.”
The InnoPreP™ offer will be presented by the Servier team at the CPHI exhibition (Servier booth: 1J30) to be held from 9 to 11 October 2018 in Madrid, Spain.
Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). With a strong international presence in 149 countries and a turnover of 4.152 billion euros in 2017, Servier employs 21,700 people worldwide. Entirely independent, the Group reinvests 25% of its turnover (excluding generic drugs) in research and development and uses all its profits for development. Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neuropsychiatric diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development.
About Servier Contract Development & Manufacturing
Servier is an international, independent pharmaceutical company that brings six decades of expertise to its embedded contract development and manufacturing business. Servier leverages this experience in offering integrated development, manufacturing, packaging and supply chain services for drug substance and drug product. It has a global network of accredited sites supporting presence in 149 countries, and has launched more than 50 commercial products.
More information on InnoPreP™ and Servier’s contract development and manufacturing business can be found at http://www.servier-cdmo.com